Peripheral T cell lymphomas (PTCL) have a poorer prognosis after conventional treatment than do highgrade B cell lymphomas. The place for high-dose therapy (HDT) with autologous stem cell support in these patients is still not clear. Forty patients, 10 women and 30 men, median age 41.5 years (range 16-61) with PTCL were treated with HDT and autologous stem cell support at The Norwegian Radium Hospital, Oslo, Norway and The University Hospital, Uppsala, Sweden, between February 1990 and September 1999. The histologic subtypes were: PTCL unspecified, 20 patients; intestinal, two patients; angioimmunoblastic (AILD), two patients; angiocentric, two patients and anaplastic large cell lymphoma (ALCL), 14 patients. All patients had chemosensitive disease and had received anthracycline-containing regimens prior to transplantation. At the time of HDT, 17 patients were in first PR or CR and 23 were in second or third PR or CR. Conditioning regimens were BEAM in 15 patients, BEAC in 14 patients, cyclophosphamide and total body irradiation (TBI) in eight patients, BEAC, without etoposide and TBI in one patient and mitoxantrone and melphalan in two patients. There were three (7.5%) treatment-related deaths. The estimated overall survival (OS) at 3 years was 58%, the event-free survival (EFS) 48% and the relapse-free survival (RFS) 56%, with a median followup of 36 months (range 7-100) for surviving patients. The patients with ALCL tended to have a better prognosis compared to those with other PTCL subtypes, OS 79% vs 44%, respectively. In conclusion, patients with chemosensitive PTCL who are failing to achieve CR with first-line chemotherapy or are in relapse can successfully be treated with HDT and autologous stem cell support. Bone Marrow Transplantation (2001) 27, 711-716.
Peripheral T cell lymphomas (PTCL) account for 10-15% of all non-Hodgkin's lymphomas (NHL) in the Western population.
1,2 PTCL are generally described as aggressive with disseminated disease at diagnosis and poor survival when treated with the same regimens as high-grade B cell lymphomas. [3] [4] [5] [6] [7] [8] However, PTCL are a heterogeneous group of lymphomas whose aggressiveness may vary depending on subtype. Anaplastic large cell lymphomas (ALCL) constitute a subgroup of PTCL with better response to treatment and overall survival. 1, 9 The recognition of the PTCL as distinct entities in the REAL classification allows the possibility of determining the clinical course and the optimal treatment of these patients. 10, 11 The place for high-dose therapy (HDT) with stem cell rescue in this group of patients is not clear. Promising results have been reported in a small number of children and adults with unspecified PTCL. 8, 12, 13 Furthermore, based on a registry analysis from the European Group for Blood and Marrow Transplantation (EBMT) on T and null cell ALCL, HDT was suggested for chemosensitive patients in CR or PR. 14 In order to obtain more knowledge about HDT in PTCL we undertook an analysis of the adult patients with PTCL treated at The Norwegian Radium Hospital, Oslo, Norway and at The University Hospital, Uppsala, Sweden.
Patients and methods

Patients
Between February 1990 and September 1999, 40 patients with PTCL were treated with HDT at The Norwegian Radium Hospital, Oslo, Norway (n = 23) and at The University Hospital, Uppsala, Sweden (n = 17). The median age at diagnosis was 41 years (range 15-59). Patient characteristics are described in detail in Table 1 . Stage at diagnosis was defined according to the Ann Arbor staging system. 15 Eligibility criteria for HDT were: age between 15 and 65 years, WHO performance status р1, adequate cardiac, hepatic and renal function. The indications for HDT were: (1) patients with chemosensitive first or subsequent relapses; (2) patients in first remission who needed more than one chemotherapy regimen to achieve either PR or CR; or (3) patients with high-risk first CR defined by an age-adjusted Male  30  75  Female  10  25  Histopathology  PTCL-unspecified  20  50  ALCL  14  35  Intestinal  2  5  AILD  2  5  Angiocentric  2  5  Stage  I  3  7  II  9  22  III  7  18  IV  21  53  B symptoms  23  59  Bulky disease у10 cm  13  33  Sites of extranodal disease  Skin  6  15  Lung  5  13  Liver  5  13  Bone marrow  4  10  Intestine  3  8  Pleura  3  8  Pericard  3  8  Kidney  2  5  Other   a   3  8  Age-adjusted IPI  0  6  1 5  1  1 1  2 7  2  1 1  2 7  3  7  1 8  Unknown  5  13 a Ovary, CNS, pancreas. IPI = The International Prognostic Index.
international prognostic factor index (age-adjusted IPI) у2 16 (Table 1) .
Histopathology
All specimens, except one, were reviewed and classified according to the REAL classification. 10 The one patient was classified as having a high-grade malignant T cell lymphoma in 1990 (according to Kiel classification) and the diagnostic tissue could not be found for review. Only patients with NHL morphology and a proven T cell phenotype or ALCL with null cell phenotype as defined by immunohistochemistry were included in the study. There were 20 patients with unspecified PTCL, of whom one patient had positive serology for HTLV1, 14 with ALCL (T or null cell type), two with intestinal T cell lymphoma, two with angioimmunoblastic T cell lymphoma (AILD) and two with angiocentric T cell lymphoma (Table 1) . One patient was treated for acute leukaemia as a child. At the age of 29, he developed unspecified PTCL. One patient had a primary diagnosis of Hodgkin's disease, nodular sclerosis type II. At first relapse, ALCL of T cell type was diagnosed.
Clinical features of the patients
The majority of the patients had advanced disease at diagnosis (Table 1) . Extranodal involvement was present in 23/40 (58%) patients, of whom seven had involvement of two sites, one of three sites and one patient of four sites. One patient had CNS involvement at diagnosis and one had CNS lymphoma as the only site of relapse. Six patients had previous bone marrow (BM) involvement; four at diagnosis and two at relapse. None of the patients with ALCL had localised primary cutaneous forms but stage II with bulky disease (n = 5), stage III (n = 3) or stage IV (n = 6). Both patients with the AILD-type PTCL had stage IVB disease with extranodal involvement (bone marrow, liver and bone marrow, CNS), respectively. The age-adjusted IPI could be retrospectively evaluated in 88% of patients: performance status, stage of disease and pretreatment serum LDH value.
Previous therapy and response
All patients had received anthracycline-containing regimens, mainly CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone), VACOP-B (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomycin), MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomycin), and one patient was treated with sequential high-dose chemotherapy according to Gianni et al. 17 Second-line chemotherapy was mainly MIME (methyl-GAG, ifosfamide, methotrexate and etoposide), DHAP (cytarabine, cisplatin and prednisone), ENAP (mitoxantrone, cytarabine, etoposide and prednisone) or the BMF protocol. 18 One patient whose only site of relapse was the CNS was treated with high-dose methotrexate, cytarabine and radiotherapy according to DeAngelis et al. 19 Ten patients received local radiotherapy as part of first-and/or second-line treatment (Table 2) .
Time from diagnosis to HDT was a median of 12 months (range 4-69). Seventeen patients were treated with HDT in first CR or PR; 13 mainly due to progressive disease or less than 50% response on first-line treatment who therefore needed more than one chemotherapy regimen to achieve PR or CR. Four patients were considered to have highrisk disease at diagnosis (age-adjusted IPI у2). The other patients were transplanted in chemosensitive relapse; 14 patients were in 2nd CR, three were in 3rd CR and six were in 2nd PR ( Table 2 ).
The HDT procedure
The source of stem cells was BM in six patients, BM and peripheral blood progenitor cells (PBPC) in two patients and PBPC in 32 patients (Table 2) . BM was used as stem cell source before the peripheral stem cell technique was established or when the patient failed to mobilise PBPC. In 13 patients, purging of the stem cell product was performed. Four of the six with previous BM involvement received a purged graft. Ten patients received selected CD34 ϩ cells from PBPC by the use of the Ceprate SC stem cell concentrator (CellPro, Europe, Brussels, Belgium) 20 or the Isolex 300I device (Baxter, Irvine, CA, USA) 21 and three received bone marrow purged with monoclonal antibodies and immunomagnetic beads. 21, 22 The conditioning regimen was BEAM (carmustine, etoposide, cytarabine, melphalan) in 15 patients, BEAC (carmustine, etoposide, cytarabine, cyclophosphamide) in 14 patients, BEAC, without etoposide and total body irradiation (TBI) administered as a single fraction of 7.5 Gy in one patient, cyclophosphamide and TBI in fractionated doses (1.3 Gy twice daily during 5 days) for a total of 13 Gy in eight patients and two patients received melphalan and mitoxantrone according to Gianni et al. 17 
Treatment after transplantation
Nine patients were treated with local radiotherapy (RT), one with RT and ␣-interferon and one with ␣-interferon only.
Evaluation and response criteria
Before HDT, all patients underwent physical examination, chest radiography, abdominal and pelvic CT scanning (and Bone Marrow Transplantation chest CT scanning if indicated), ultra sound of upper abdomen, liver, spleen and bone marrow biopsy.
CR was defined as the complete disappearance of all measurable radiographic or clinical evidence of disease. PR was defined as a reduction in tumour mass by more than 50%, measured as the sum of the product of the two largest perpendicular diameters of the tumours or the degree of bone marrow infiltration by lymphoid cells. Progression was defined as at least 25% increase in previously noted tumour mass or the appearance of any new lesion. Response of disease to HDT was assessed 3 months after the date of stem cell reinfusion. Routine follow-up with restaging was carried out every 3 months for the first year, every 4 months for the next year and every 6 months up to 5 years and then yearly after HDT or whenever clinically indicated.
Statistical methods
Survival curves were made according to the Kaplan-Meier method with the use of SPSS 9.0 for Windows (SPSS, Chicago, IL, USA). Analysis was performed on all data obtained as of 10 April 2000. Relapse-free survival (RFS) was calculated from the time of HDT to relapse, or to the date of last follow-up. Event-free survival (EFS) was calculated from the time of HDT to relapse, procedure-related death or to the date of last follow-up. Overall survival (OS) was calculated from the time of HDT to death from any cause or date of last follow-up. Differences between survival curves were analysed by the log rank test. The MannWhitney test was used for comparison of groups. P values Ͻ0.05 were considered as statistically significant.
Results
Response and survival
Thirty-two patients (80%) achieved or maintained a CR after HDT. Currently, relapse has occurred in 16 patients, all within 2 years after transplantation. The estimated overall survival (OS) at 3 years was 58% (Figure 1 ), the event- free survival (EFS) was 48% ( Figure 2 ) and the relapsefree survival (RFS) was 56%. The median follow-up of all patients from reinfusion of stem cells was 25 months (range 0-100) and of the 25 patients currently alive, 36 months (range 7-100). There were three (7.5%) procedure-related deaths; one patient died of myocardial infarction and fungal septicaemia 7 days after transplantation, one developed fever, liver function abnormalities, leukopenia and trombocytopenia 1 month after the HDT and died of multiorgan failure at 3 months; autopsy was not done. One patient developed severe congestive heart failure and lung fibrosis after the HDT and died in remission 11 months after the HDT. Additionally, one patient who was diagnosed with unspecified PTCL, which displayed the phenotype of peripheral T lymphocytes, died from T-ALL, 7 months after HDT which displayed the phenotype of precursor T lymphocytes. Autopsy showed no evidence of lymphoma.
Patients with ALCL tended to have better OS compared to other PTCL histologies, 79% vs 44%, respectively. The difference, however was not significant (P = 0.08) ( Figure  3 ). Univariate analysis revealed no significant differences in OS, RFS or EFS with respect to disease status at transplant (CR vs PR, CR1 vs other disease status or CR1/PR1 vs other disease status). Furthermore, no significant differences in survival were observed with regard to transplanting hospital, number of extranodal sites (0, 1 vs у2), risk categories according to age-adjusted IPI, stage (I, II vs III, IV), B symptoms, sex, purging of the stem cell product or type of conditioning regimen. There have so far been fewer relapses in the group receiving selected CD34 ϩ cells compared to the other patients, 30% vs 43% (P = 0.5). The CD34 ϩ group had a higher median age at HDT (48 years vs 40 years), more patients in advanced stages (80% vs 67%), higher age-adjusted IPI score у2 (60% vs 40%), higher number transplanted in complete remission (90% vs 63%) and a higher number with ALCL (40% vs 33%). The CD34 ϩ group also has a longer median follow-up after HDT than the rest of the patients, 32.5 months vs 21 months, respectively.
Engraftment
Haematopoiesis recovered in all patients. The median time to reach an absolute neutrophil count (ANC) of 0.5 ϫ 10 
Discussion
PTCL have, in general, been treated like high-grade lymphoma of B cell origin with CHOP or CHOP-like regimens, but certain subtypes including AILD and small T cell variants have even been treated with less aggressive regimens, often with poor results. 6, 7 According to the REAL classification 2,9 the PTCL have a significantly poorer prognosis than diffuse large B cell lymphomas. Some investigators have therefore suggested that patients with PTCL should receive more intensive treatment such as HDT with autologous stem cell support, even in first remission. 1, 2 Due to the low incidence of PTCL, the experience of most single centres on HDT is limited. The literature comprises a few articles and abstracts on HDT in PTCL in general 13, 23, 24 or in histological subgroups. 25, 26 Therefore, The Norwegian Radium Hospital and The University Hospital Uppsala gathered the data of their patients in a common database in order to analyse the results of HDT, not only in ALCL, but also in the other subgroups of PTCL. To our knowledge, this is one of the larger studies of HDT in PTCL.
Although studies with small numbers of patients cannot directly be compared, the overall survival of 58% in our study compares favourably with the relatively limited data reported in the literature, eg by Vose et al 13 of 17 adult patients with T cell lymphoma. This indicates that long lasting remissions can be achieved after HDT in patients with PTCL with an aggressive clinical presentation or respon-sive relapse. It is also noteworthy that the results of HDT achieved in PTCL are similar to those of HDT in highgrade B cell lymphoma. 27 Some authors have suggested that HDT should be performed in PTCL as consolidation of first remission. 1, 2, 14 The outcome in our study did not differ significantly in patients who received HDT in first or subsequent remissions. However, the number of patients with PTCL in our study does not allow a conclusion regarding the optimal time to perform HDT. This question can only be answered from the results of prospective studies.
The REAL classification has recognised T and null cell ALCL as a distinct entity among the PTCLs. 10 Generally, ALCL are reported to have advanced disease at diagnosis, being clinically aggressive, but the patients have a higher complete response rate to conventional therapy and longer survival than the other subtypes of PTCL. 1, 9, 28, 29 The prognosis, however, is poor for patients not achieving CR, and for the 25-45% of patients who relapse after conventional therapy. [29] [30] [31] Earlier reports on the use of HDT have been sparse and concern few cases treated in relapse. 30, [32] [33] [34] One study has tested HDT as 'upfront' consolidation in chemosensitive ALCL in order to sustain first CR and prevent relapse. 25 With this approach they achieved a CR rate above 90% and no late relapses. 25, 35 According to these data and the larger EBMT registry study 14 we analysed the outcome of the 14 patients with ALCL in our study. The ALCL group tended to have a better overall survival than the other PTCL subtypes (Figure 3 ). The OS of the ALCL group was comparable to the OS of 76% of the 64 patients with T and null cell ALCL in the EBMT registry study. 14 The results indicate that more than 70% of patients with ALCL might be cured by HDT.
The age-adjusted IPI could not predict the prognosis of the patients in our study, which was also the case in the EBMT registry study. 14 The initial report of the IPI 16 neither took into account the immunophenotype nor its relation to response and survival. Later, two studies have confirmed that the IPI can also be applied for PTCL. 2, 36 However, the IPI was prepared for patients treated with conventional therapy, and might therefore not be relevant for patients who receive HDT. Other factors independent of IPI may have an impact on prognosis. The expression of Epstein-Barr virus genome in T cell lymphomas appears to be an unfavourable prognostic variable independent of IPI. 37 The importance of purging of the stem cell product in malignant lymphoma is still under discussion since results from prospective randomised trials are lacking. [38] [39] [40] In the present study, purging of the autografts was performed in 13 of the 40 patients. Time to engraftment was similar to those who received unmanipulated grafts, indicating that purging did not affect the grafts negatively. Although not statistically significant, fewer relapses were observed in the group receiving selected CD34 ϩ cells. Among the patients who received selected CD34 ϩ cells, a higher number of patients were in CR at time of transplant. Whether remission status or the effect of purging favoured patient outcome cannot be answered by this study.
In conclusion, the results of HDT for patients with chemosensitive PTCL are promising. Patients with PTCL Bone Marrow Transplantation have similar survivals after HDT as do patients with aggressive B cell lymphoma. HDT for PTCL should ideally be tested out in a randomised study, but the small number of PTCL may preclude such studies. Larger EBMT registry studies may help to clarify whether HDT should be considered standard therapy or not for this lymphoma entity.
